BACKGROUND: Despite aggressive multimodality treatment, 5-year survival of stage III non-small cell lung cancer (NSCLC) remains <30%. To detect relapse, progression, or development of a second primary cancer early, many clinicians perform follow-up scans. To assess the impact of routine scanning, we compared clinical trial patients who had study-mandated scans with those treated off-study who had less intensive radiologic follow-up. METHODS: The hospital cancer registry and trials databases were searched for patients with locally advanced NSCLC who had undergone multimodality treatment with curative intent. Baseline demographics were collected as well as frequency and results of clinical and radiologic follow-up. RESULTS: Forty trial patients and 35 nontrial control patients were identified. Trial patients underwent significantly more imaging, particularly in the first 2 years (2.9 versus 2.0 body scans per year, p = 0.0016; 1.1 versus 0.4 brain scans per year, p < 0.001) but did not have more frequent follow-up visits. Forty-five cancers were detected (41 relapses, four metachronous primary tumors) in 44 (59%) patients. Of these, 28 (64%) sought medical attention that led to detection before a scheduled appointment or procedure. There was no significant difference in time to relapse or second primary in trial and nontrial patients (p = 0.80). Twenty-three patients had localized relapse, but only 15 could be treated with curative intent. Despite the trial group demonstrating a higher number of asymptomatic cancers and being offered potentially curative therapy more frequently, there was no significant difference in survival between trial and nontrial patients. CONCLUSION: In patients with locally advanced NSCLC, frequent cross-sectional imaging does not alter survival after combined modality therapy.
BACKGROUND: Despite aggressive multimodality treatment, 5-year survival of stage III non-small cell lung cancer (NSCLC) remains <30%. To detect relapse, progression, or development of a second primary cancer early, many clinicians perform follow-up scans. To assess the impact of routine scanning, we compared clinical trial patients who had study-mandated scans with those treated off-study who had less intensive radiologic follow-up. METHODS: The hospital cancer registry and trials databases were searched for patients with locally advanced NSCLC who had undergone multimodality treatment with curative intent. Baseline demographics were collected as well as frequency and results of clinical and radiologic follow-up. RESULTS: Forty trial patients and 35 nontrial control patients were identified. Trial patients underwent significantly more imaging, particularly in the first 2 years (2.9 versus 2.0 body scans per year, p = 0.0016; 1.1 versus 0.4 brain scans per year, p < 0.001) but did not have more frequent follow-up visits. Forty-five cancers were detected (41 relapses, four metachronous primary tumors) in 44 (59%) patients. Of these, 28 (64%) sought medical attention that led to detection before a scheduled appointment or procedure. There was no significant difference in time to relapse or second primary in trial and nontrial patients (p = 0.80). Twenty-three patients had localized relapse, but only 15 could be treated with curative intent. Despite the trial group demonstrating a higher number of asymptomatic cancers and being offered potentially curative therapy more frequently, there was no significant difference in survival between trial and nontrial patients. CONCLUSION: In patients with locally advanced NSCLC, frequent cross-sectional imaging does not alter survival after combined modality therapy.
Authors: Traves D Crabtree; Varun Puri; Simon B Chen; David S Gierada; Jennifer M Bell; Stephen Broderick; A Sasha Krupnick; Daniel Kreisel; G Alexander Patterson; Bryan F Meyers Journal: J Thorac Cardiovasc Surg Date: 2014-08-08 Impact factor: 5.209
Authors: Leah M Backhus; Farhood Farjah; Chao-Kang Jason Liang; Hao He; Thomas K Varghese; David H Au; David R Flum; Steven B Zeliadt Journal: J Surg Res Date: 2015-06-25 Impact factor: 2.192
Authors: Leah M Backhus; Farhood Farjah; Steven B Zeliadt; Thomas K Varghese; Aaron Cheng; Larry Kessler; David H Au; David R Flum Journal: Ann Thorac Surg Date: 2014-10-03 Impact factor: 4.330